NSE · REMUS · Pharmaceuticals
Remus Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹625 Cr with net profit ₹29 Cr — a 4.65% net margin, versus 9.88% the period before.
Shareholding
As of 2026-03-31
- Promoter70.95%
- Public22.93%
- FII5.28%
- DII0.83%
2,009 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.7× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #1 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,48,028 Cr | 35.46 | 5.36 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,13,227 Cr | 23.19 | 4.18 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,11,186 Cr | 31.07 | 3.23 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,258 Cr | 96.25 | 19.86 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹98,075 Cr | 30.44 | 2.58 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹97,239 Cr | 25.72 | 2.57 | 9.25% | 10.7% |
| Lupin Limited | ₹95,939 Cr | 16.11 | 4.27 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹95,000 Cr | 44.53 | 5.83 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,185 Cr | 21.85 | 6.49 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹63,949 Cr | 28.06 | 4.63 | 16.66% | 14.31% |
| Remus Pharmaceuticals Limited(this company) | — | 46.36 | 3.52 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashRemus Pharmaceuticals Limited (REMUS) has a market capitalization of Rs 2252 Cr. The company reported revenue of Rs 625.34 Cr, representing a revenue growth of 191.3%. Its debt-to-equity ratio stands at 0.09.
Positives
- +Revenue growth was 191.3% in the latest period.
- +Debt-to-equity ratio is low at 0.09, indicating sound financial leverage.
- +Promoter holding is high at 70.95% as of March 31, 2026.
- +The Return on Capital Employed (ROCE) is 21.6%.
Negatives
- −Promoter shareholding has decreased from 70.85% in March 2025 to 70.95% in March 2026.
- −No quarterly results have been disclosed.
Financial performance
Remus Pharmaceuticals Limited reported revenue of Rs 625.34 Cr in the latest financial period. This represents a substantial revenue growth of 191.3%. The Earnings Per Share (EPS) for the latest period is Rs 20.97.
Balance sheet
The company maintains a low debt-to-equity ratio of 0.09, suggesting limited reliance on borrowed capital. The book value per share is Rs 276.4.
Profitability & Returns
Remus Pharmaceuticals Limited has a Return on Capital Employed (ROCE) of 21.6%. The company's P/E ratio is 34.28 based on its EPS of Rs 20.97.
Ownership & Pledges
The public shareholding stands at 22.93%. There are no promoter pledged shares reported.
Data as of — price: 2026-09-17 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Remus Pharmaceuticals Limitedshare price & fundamentals